Celia Pinto-Díez

Celia Pinto-Díez

Auto-generated profile, based on publicly available information

Celia Pinto-Díez

Servicio de Bioquímica-Investigación, IRYCIS-Hospital Ramón y Cajal, Madrid, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PDF file
EGEva M García-Recio
Eva M García-Recio
CPCelia Pinto-Díez
Celia Pinto-Díez
MPM Isabel Pérez-Morgado
M Isabel Pérez-Morgado
MGMarta García-Hernández
Marta García-Hernández
GFGerónimo Fernández
Gerónimo Fernández
Victor GonzalezVictor Gonzalez
Victor Gonzalez
Elevated expression levels of eukaryotic initiation factor 4E (eIF4E) promote cancer development and progression. MAP kinase interacting kinases (MNKs) modulate the function of eIF4E through the phosphorylation that is necessary for oncogenic transformation. Therefore, pharmacologic MNK inhibitors may provide a nontoxic and effective anticancer strategy. MNK1b is a truncated isoform of MNK1a that is active in the absence of stimuli. Using in vitro selection, high-affinity DNA aptamers to MNK1b were selected from a library of ssDNA. Selection was monitored using the enzyme-linked oligonucleotide assay (ELONA), and the selected aptamer population was cloned and sequenced. Four groups of aptamers were identified, and the affinities of one representative for rMNK1b were determined using ELONA and quantitative polymerase chain reaction. Two aptamers, named apMNK2F and apMNK3R, had a lower Kd in the nmol/l range. The secondary structure of the selected aptamers was predicted using mFold, and the QGRS Mapper indicated the presence of potential G-quadruplex structures in both aptamers. The selected aptamers were highly specific against MNK1, showing higher affinity to MNK1b than to MNK1a. Interestingly, both aptamers were able to produce significant translation inhibition and prevent tumor cell proliferation and migration and colony formation in breast cancer cells. These results indicate that MNK1 aptamers have an attractive therapeutic potential.

5 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
CPCelia Pinto-Díez
Celia Pinto-Díez
EGEva M. García-Recio
Eva M. García-Recio
MPM. Isabel Pérez-Morgado
M. Isabel Pérez-Morgado
MGMarta García-Hernández
Marta García-Hernández
LSLara Sanz-Criado
Lara Sanz-Criado
MMMaria Elena Martín
Maria Elena Martín
Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer